Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.
Mier
James W
JW
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy; D008545:Melanoma / Q000276:immunology / Q000628:therapy; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy; D016896:Treatment Outcome
D007376:Interleukin-2; D016178:Granulocyte-Macrophage Colony-Stimulating Factor